Nevertheless, despite these limitations, our study represents one of the largest AMH analyses and with the longest follow-up conducted so far among breast cancer patients; plasma samples were prospectively collected at predefined timepoints during treatment and oncologic follow-up up to 3 years after diagnosis in a homogenous cohort of women. The gene discussed is AMH; the disease is breast carcinoma.